Ticker brief

NTLA INTELLIA THERAPEUTICS INC

Consumer, Non-cyclical · Biotechnology

last close
$12.87
1 day
-1.8%
14 days
+8.1%
mkt cap
$2.5B
signals 14d
10
authors 14d
8
crowd 14d
-0.2σ
Options inteloptions-surface reads · latest available day per source
metricreadingcontext
IV — ATM 30d114% rich · 92 pctile own 1yIV/HV 1.94× (as of 2026-08-27)
Skew — 25Δ RR 30d+0.065 51 pctile own 1ybalanced vs own range
Net dealer OI (NDOI)+3.10 elevated5-session Δ +0.71 (as of 2026-07-06)
OI alarmquietlast alarm 2026-04-28 (z=2.9)
Next earnings2026-11-05 (proj)in 69d
Sentiment — last 14 days
daily mean sentiment, 2026-08-15 → 2026-08-28 · now +0.60 (−1 bearish … +1 bullish)
Who spoke8
authorgradetrader scoresignalsmean sent
@SixSigmaCapitalB-0.403-0.20
@AlphaScout360C-4.451+0.80
@alphachartsB-3.111+0.00
@beach_tradesC-0.041+0.25
@hiddensmallcapsB-0.771+0.40
@PSInvestorB-1.481+0.30
@Sir_KoryC-0.111+0.50
@OwenGregorianC-1.781+0.60
Recent signals10of 10 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-08-28@OwenGregorian+0.60Intellia's Phase 3 therapy cut attacks 87% versus placebo and entered a rolling FDA submission.
2026-08-25@Sir_Kory+0.50Frames gene editing as a large long-term market and compares four public platforms by maturity and risk.-4.7%
2026-08-23@SixSigmaCapital-0.70Reviews a past healthcare basket, including TWST gains and a realized 50% NTLA loss.+0.2%
2026-08-21@PSInvestor+0.30Reports ARK Invest's dated buy list; output is capped at the six directly listed purchases.+0.2%
2026-08-21@hiddensmallcaps+0.40Compares gene-editing basket valuations with IONQ to argue biotech sentiment has room to improve.+0.2%
2026-08-21@beach_trades+0.25Directs NTLA observers to CRSP's move, implying a favorable peer read-through.+0.2%
2026-08-19@SixSigmaCapital-0.30Calls VKTX a good idea while noting a negative past experience with NTLA.-3.1%
2026-08-19@SixSigmaCapital+0.40Offers NTLA and PRME as highly speculative bullish candidates.-3.1%
2026-08-19@alphacharts+0.00Identifies a giant inverse head-and-shoulders base in CRSP.-3.1%
2026-08-15@AlphaScout360+0.80Bullish NTLA entry now, targeting a test of $28. — Identifies the current price as an asymmetric bullish entry with a $28 target.+8.1%

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.